Posted by ABMN Staff on Apr 24th, 2024
Biohaven (NYSE:BHVN – Free Report) had its price target boosted by UBS Group from $59.00 to $60.00 in a research report sent to investors on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock.
Several...
More of this article »